1. Systemic activation of the complement system in patients with advanced age-related macular degeneration
- Author
-
V. Michael Holers, Jennifer N. Cathcart, Brandie D. Wagner, Marc T Mathias, Ashley Frazer-Abel, Alan G. Palestine, Naresh Mandava, Anne M. Lynch, Jennifer L. Patnaik, and Frank S Siringo
- Subjects
0301 basic medicine ,Male ,Enzyme-Linked Immunosorbent Assay ,Complement Membrane Attack Complex ,03 medical and health sciences ,0302 clinical medicine ,Age related ,Geographic Atrophy ,Odds Ratio ,Medicine ,Humans ,In patient ,Fluorescein Angiography ,Complement Activation ,Aged ,Aged, 80 and over ,business.industry ,General Medicine ,Macular degeneration ,medicine.disease ,Choroidal Neovascularization ,Complement (complexity) ,Complement system ,Geographic atrophy ,Ophthalmology ,030104 developmental biology ,Immunology ,030221 ophthalmology & optometry ,Complement C3a ,Wet Macular Degeneration ,Female ,business ,Tomography, Optical Coherence ,Complement Factor B - Abstract
Purpose: To examine the role of systemic activation of the complement system (assessed by levels of circulating C3a, Ba, and sC5b-9) in patients (n = 122) with advanced age-related macular degeneration, geographic atrophy, and neovascular age-related macular degeneration, compared with cataract controls (n = 27). Methods: Plasma complement factors were measured using enzyme-linked immunosorbent assays. Statistical analysis included univariate and multivariate logistic regression (p Results: Adjusted for age, the odds ratios of C3a and sC5b-9 for any advanced age-related macular degeneration were 1.78 (95% confidence interval = 1.16–2.73, p Conclusion: We suggest a role for elevated plasma levels of C3a and sC5b-9 in patients with neovascular age-related macular degeneration. The study’s results reinforce the need for more investigation to assess the impact of therapeutic interventions targeted at the complement signaling pathways in age-related macular degeneration.
- Published
- 2019